Upload
nathan-johnson
View
222
Download
0
Tags:
Embed Size (px)
Citation preview
Molecular Imaging and Therapy with Perfluorocarbon Nanoparticulates:
Environmental Impact.
Washington University Medical School
Saint Louis, MO
GENERALIZED TARGETING PARADIGMGENERALIZED TARGETING PARADIGM
Targeting system: “Molecular zip codes”(MAb, aptamers, small peptides, peptidomimetics, polysaccharides, etc)
PayloadsImaging agents (Gd3+)DrugsRadionuclides 19FGd3+Lipid coatAnti-fibrinAnti-tissue factorAnti−αvβ3-integrin
Liquid VentilationVitreous
Replacement
Perfluorocarbon Biomedical Applications
Before After
0.5 µ 0.5 µ 0.5 µ
RBC
Fibrin
TargetedContrast
Control Thrombus Targeted Thrombus
1 mm
Clot
Suture1 mm
Clot
Suture
Scanning EMclot labeled with fibrin targeted nanoparticles
Ultrasound contrastenhancement of fibrin clot in vitro using conventional clinical scanner (7.5 MHz)
Fibrin Imaging
Targeted Nanoparticles Support Enormous Paramagnetic Payloads
Targeted Targetedαβ3- Non-α β - Non-
mM)-1 [Particle] 1,800,000 1,950,000
r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000
94,400 92,400Gd3+Ions / Particle 94,400 92,400Gd3+Ions / Particle
19.1 21.1r1 (s*mM)-1 [Gd] 19.1 21.1r1 (s*mM)-1 [Gd]
22.9 24.6r2 (s*mM)-1 [Gd] 22.9 24.6r2 (s*mM)-1 [Gd]
r1 (s*mM)-1 [Particle] 1,800,000 1,950,000r1 (s*mM)-1 [Particle] 1,800,000 1,950,000
r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000
α β - Non-α β - Non-α β - Non-α β - Non-
mM)-1 [Particle] 1,800,000 1,950,000
r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000
94,400 92,400Gd3+Ions / Particle 94,400 92,400Gd3+Ions / Particle
19.1 21.1r1 (s*mM)-1 [Gd] 19.1 21.1r1 (s*mM)-1 [Gd]
22.9 24.6r2 (s*mM)-1 [Gd] 22.9 24.6r2 (s*mM)-1 [Gd]
r1 (s*mM)-1 [Particle] 1,800,000 1,950,000r1 (s*mM)-1 [Particle] 1,800,000 1,950,000
r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000
mM)-1 [Particle] 1,800,000 1,950,000
r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000
94,400 92,400Gd3+Ions / Particle 94,400 92,400Gd3+Ions / Particle
19.1 21.1r1 (s*mM)-1 [Gd] 19.1 21.1r1 (s*mM)-1 [Gd]
22.9 24.6r2 (s*mM)-1 [Gd] 22.9 24.6r2 (s*mM)-1 [Gd]
r1 (s*mM)-1 [Particle] 1,800,000 1,950,000r1 (s*mM)-1 [Particle] 1,800,000 1,950,000
r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000r2 (s*mM)-1 [Particle] 2,160,000 2,270,000
Detection of Angiogenesis in the Vx-2 Model
Masses Seen By MRI Were Not Always Vx-2 Tumors
T2-Weighted MRIAfter
avB3-Nanoparticles
5 mm5 mm
Histology Revealed Rejected Tumor Infiltrated with Inflammatory Cells
No Molecular Imaging of No Molecular Imaging of Angiogenesis for Tumors in Angiogenesis for Tumors in
RejectionRejection
Histology Revealed Rejected Tumor Infiltrated with Inflammatory Cells
Melanoma Angiogenesis: Detection With αvβ3 Integrin-Targeted Paramagnetic NanoparticlesMouse Imaging @ 1.5T
Angiogenesis around 2 mm melanoma tumor
2 mm tumor
syringe
Time 0 min
Time 120 min
Time course
1
1
1
1
1
1
J
J
J
J
J
J
H
H
HH
H
H0
20
40
60
80
100
120
140
160
180
0 20 40 60 80 100 120
1 Targeted
J Control
H Competition
Time course of MRI Contrast Enhancement P
erce
nt
En
han
cem
ent
Time (min) Post Injection
Site-Targeted Drug Delivery
D
Target Cell
D
D
0.5 µ
2. Particles bind to cell surface
1. Load with drug 3. Drug effect
Targeting Element
Drug Loaded Outer
Lipid Monolayer
Exchange of
Lipids and Drug
Components
Target Cell Membrane
Epitopes
Novel Mechanisms Of Drug Delivery: “Contact Facilitated Drug Delivery*”
Rhodamine-labeled NP
GFP-linked endocytotic markers rab5 and rab7 in transfected
C32 melanoma cells
*Lanza GM, Wickline SA et al: Targeted antiproliferative drug delivery to vascular smooth muscle cells with magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002; 106:2842-2847
Antiproliferative Effects of Free versus Tissue Factor - Targeted Paclitaxel Nanoparticles on
Vascular Smooth Muscle Cells
Control Taxol 0.2 mol % Taxol 2.0 mol %0
5
10
15
20
25
30C
EL
L C
OU
NT
X 1
0,0
00
NANOPARTICLE FORMULATION
NON -TARGETED NANOPARTICLES
TARGETED NANOPARTICLES
* *
Control3/3
αβ3DXR-NP(4/4)
Rejection of Mouse Melanoma 7d following αβ3-Targeted, DXR, Paramagnetic Nanoparticles
Proton and Fluorine Imaging
Proton Imaging Fluorine Imaging
Clot
y = 0.2665x - 2.1857R2 = 0.9462
-10010203040
0 20 40 60 80 100Emulsion percentage
y = 0.0493x - 0.641R2 = 0.9178
-2
0
2
4
6
0 25 50 75 100Estimated % of Emulsion Volume
15:5 Crown-Ether
PFOB
Dosimetry of Targeted Nanoparticle Levels
Alliance Pharmaceutical
Oxygent Production
Typical Pharmaceutical Emulsification Process
President Bush: reduce the greenhouse gas intensity of the U.S. economy by 18% over the next ten years.
Perfluorocarbons have 10,000 times the global warming impact of carbon dioxide
Major PFC applications:
• electronic insulators
• aluminum smelting
• refrigerants
• subsurface barrier testing
EPA suggested four options for its formal definition of "leak rate." :
• "annualizing" method.
• "rolling-average" method
• the higher calculated leak rate.
• consistent method
Non-VOC with no significant participation in ozone formation in ambient air.
MedicalGregory Lanza, MD, PhDSamuel Wickline, M.D.
TechnicalMary Watkins, R.T. (MR)Todd Williams, B.S., R.T. (MR)Rosa Lin, M.S.Brian Hennery, B.S.Ralph FuhrhopHuiying Zhang, M.D.Stacy Allen, B.S.Liz Lacy, B.S.Peggy Brown, RDCSMichael Scott, BSAnne Schmeider, M.S.Kathy Crowder, MS
MR & US SciencePatrick Winter, Ph.D.Michael Hughes, Ph.DJon Marsh, Ph.DFrank Hockett, M.S.E.E.Michal Lijowski PhDGrace Hu, M.S.Anagana Pan Ph.D
WU Personnel
Key Collaborators
Philips Medical Systems
David Rollo MD
Horace Hines PhD
Ling Shao PhD
Carmen van Vilsteren PhD
Christopher Hall PhD
Shelton Caruthers PhD
The Dow Chemical Co.
Jaime Simon PhD
Garry Kiefer PhD
Phillip Athey PhD
Gyongyi Gulyas PhD
Keith Frank PhD
Consultants
Sam Achilefu PhD
Wynn Volkert PhD
Richard Holmes PhD
Patrick Gaffney PhD
Bristol-Myers Squibb Medical Imaging
D. Scott Edwards
Stephen Haber
Thomas Harris